222 related articles for article (PubMed ID: 30725538)
1. Levetiracetam-Associated Psychogenic Non-epileptic Seizures; A Hidden Paradox.
Jabeen SA; Gaddamanugu P; Cherian A; Mridula KM; Kumar DU; Meena AK
J Popul Ther Clin Pharmacol; 2018 Jul; 25(2):e1-e11. PubMed ID: 30725538
[TBL] [Abstract][Full Text] [Related]
2. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
[TBL] [Abstract][Full Text] [Related]
4. Lipid and thyroid hormone levels in children with epilepsy treated with levetiracetam or carbamazepine: A prospective observational study.
Nishiyama M; Takami Y; Ishida Y; Tomioka K; Tanaka T; Nagase H; Nakagawa T; Tokumoto S; Yamaguchi H; Toyoshima D; Maruyama A; Nozu K; Nishimura N; Iijima K
Epilepsy Behav; 2019 Jan; 90():15-19. PubMed ID: 30500483
[TBL] [Abstract][Full Text] [Related]
5. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
6. [Paradoxical effect of levetiracetam on seizure suppression: three cases showing U curve association between dose and effect].
Inoue T; Kobayashi K; Usami K; Shimotake A; Inouchi M; Sakai T; Ikeda A; Takahashi R
Rinsho Shinkeigaku; 2021 Apr; 61(4):247-252. PubMed ID: 33762498
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid.
Liguori C; Turner K; Izzi F; Assogna M; Canevini MP; Mercuri NB; Placidi F
CNS Neurosci Ther; 2019 May; 25(5):632-637. PubMed ID: 30675751
[TBL] [Abstract][Full Text] [Related]
8. Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia.
Cvetkovska E; Kuzmanovski I; Babunovska M; Boshkovski B; Aleksovska K; Trencevska GK
Clin Neuropharmacol; 2018; 41(6):218-221. PubMed ID: 30234559
[TBL] [Abstract][Full Text] [Related]
9. A Rare Case of Levetiracetam and Drug-Induced Idiopathic Aseptic Meningitis in a Pediatric Patient.
McDonald D; Sultan R; Viswanathan A; Siu A
Pharmacotherapy; 2019 Jan; 39(1):109-113. PubMed ID: 30488976
[TBL] [Abstract][Full Text] [Related]
10. Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy.
Kim JS; Kim WS; Sung WY; Woo H
Epilepsy Behav; 2024 May; 154():109740. PubMed ID: 38547767
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.
Kanemura H; Sano F; Aihara M
Eur J Paediatr Neurol; 2019 Jan; 23(1):197-203. PubMed ID: 30424990
[TBL] [Abstract][Full Text] [Related]
12. Utilization of brain imaging in evaluating patients with psychogenic nonepileptic spells.
Wei D; Garlinghouse M; Li W; Swingle N; Samson KK; Taraschenko O
Epilepsy Behav; 2018 Aug; 85():177-182. PubMed ID: 29981498
[TBL] [Abstract][Full Text] [Related]
13. Pediatric psychogenic non-epileptic seizures: A retrospective observational cohort study at a quaternary center.
Vasquez A; Hilliker DR; Wirrell EC
Epilepsy Behav; 2023 Sep; 146():109359. PubMed ID: 37499579
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
[TBL] [Abstract][Full Text] [Related]
15. Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy.
Hagemann A; May TW; Nieder E; Witte-Bölt K; Pohlmann-Eden B; Elger CE; Tergau F; Schulze-Bonhage A; Straub HB; Arnold S; Brandt C
Epilepsy Res; 2013 Mar; 104(1-2):140-50. PubMed ID: 22959715
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of levetiracetam because of behavioral side effects: a case-control study.
White JR; Walczak TS; Leppik IE; Rarick J; Tran T; Beniak TE; Matchinsky DJ; Gumnit RJ
Neurology; 2003 Nov; 61(9):1218-21. PubMed ID: 14610123
[TBL] [Abstract][Full Text] [Related]
17. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
[TBL] [Abstract][Full Text] [Related]
18. Anxiety and depression in psychogenic movement disorder and non-epileptic seizures: a prospective comparative study.
Grimaldi I; Dubuc M; Kahane P; Bougerol T; Vercueil L
Rev Neurol (Paris); 2010 May; 166(5):515-22. PubMed ID: 20056263
[TBL] [Abstract][Full Text] [Related]
19. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
20. Risk factors predisposing to psychotic symptoms during levetiracetam therapy: A retrospective study.
Pinckaers FME; Boon ME; Majoie MHJM
Epilepsy Behav; 2019 Nov; 100(Pt A):106344. PubMed ID: 31525554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
